



# Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,  
P.O. Tandaheeri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507  
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542

Email: [genomicvalley@gmail.com](mailto:genomicvalley@gmail.com); Visit: <http://www.genomicvalley.com>

**Dated: 30<sup>th</sup> May, 2018**

To,  
**BSE Limited,**  
PhirozeJeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai-400001  
Email ID: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

**Ref: Genomic Valley Biotech Limited (539206/ GVBL)**  
**Sub: Outcome of the Board Meeting held on 30<sup>th</sup> May, 2018**

**Dear Sir/Madam,**

Pursuant to the Regulation 30 and any other applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors at its meeting held on 30<sup>th</sup> May, 2018, has inter-alia, approved the Audited Financial Results of the Company for the Quarter and Year ended 31<sup>st</sup> March, 2018.

Further pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results of the Company for the Quarter and Year ended 31<sup>st</sup> March, 2018.

We are also enclosing a copy of the Auditor's Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforesaid Board Meeting commenced at 11:45 AM and concluded at 04:30 P.M.

This is for your information and records.

Please acknowledge the receipt.

Thanking you.

Yours faithfully,

**For and on behalf of**  
**Genomic Valley Biotech Limited**

*Hitesh*



**Hitesh Kumar**  
**Company Secretary & Compliance officer**

**Encl: A/A**



A.K. Khattar & Associates  
Chartered Accountants

112-A, Ground Floor, DDA Complex,  
Jhandewalan Extn-1, New Delhi - 110055  
Ph: 011-43570260

## INDEPENDENT AUDITOR'S REPORT

To,

The Board of Directors of  
Genomic Valley Biotech Limited  
4 K.M. Stone, Beri Chharra Road,  
Village- Kherka Musalman,  
P.O. Tandaheri, Tehsil-Bahadurgarh,  
Distt-Jhajjar, Haryana-124507

**Subject: Independent Auditor's Report on the Audited Financial Results for the Quarter and Year ended**

Biotech Limited ('the Company') for the quarter and year ended March 31, 2018 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone Ind AS financial Statement which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statements based on our audit of such standalone financial Statements.

3. We conducted our audit in accordance with the Standard on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatement.

An audit involves performing procedures to obtain audited evidence about the amount and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used in the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanation given to us, the Statement:

- (i) is presented in accordance with the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016; and
- (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and the other accounting principles generally accepted in India of the Net Profit/Loss and Total Comprehensive Income/Loss and other financial information of the Company for the Year ended March 31, 2018.



5. The Statement includes the results for the Quarter ended March 31, 2018 being the balancing figure between audited figures in respect of the full financial year and the audited year to date figures up to the third quarter of the current financial year.



For and on behalf of  
**A.K. KHATTAR & ASSOCIATES**  
Chartered Accountants

(A.K. KHATTAR)  
(Prop.)  
(Membership No.-084960)

Place: Delhi  
Date: May 30, 2018

Regd. Off: 4 F  
TEHSIL-B

Statement of Standalone Audited

Sr	Particular
I	Revenue From Operations
II	Other Income
III	Total Revenue (I+II)
IV	Expenses
	Cost of materials consumed
	Purchases of Stock-in-trade
	Changes in inventory
	Trade
	% of finished goods work-in-progress
	Employee benefits expense
	Financial costs
	Depreciation and amortization expense
	Other expenses
	Total Expenses (IV)
	Profit / (Loss) before exceptional item and tax (III-IV)
V	Exceptional item
VI	Profit/loss before Tax (V-VI)
VII	Tax expenses
VIII	(1) Current Tax
	(2) Deferred Tax
IX	Profit/ (Loss) for the period from continuing operations (VI)
X	Profit/ (Loss) from discontinued operations
XI	Tax expense of discontinued operations
XII	Profit/ (Loss) from discontinued operations (after tax) (X-XI)

TECH LIMITED  
RA ROAD, P.O. T  
AJJA  
PLC  
HARYANA  
124507  
133029

the quarter and year ended March 31, 2018


In Rs.			
Sr	Particular	For the quarter ended	
		31-Mar-17	31-Mar-18
		Un-Audited	Audited
			Audited
I	Revenue From Operations	1,233,320	5,944,430
II	Other Income	-	124,688
III	Total Revenue (I+II)	1,233,320	6,069,118
IV	Expenses	1,337,070	5,175,303
	Cost of materials consumed		
	Purchases of Stock-in-trade		
	Changes in inventory		
	Trade		
	% of finished goods work-in-progress		
	Employee benefits expense		
	Financial costs		
	Depreciation and amortization expense		
	Other expenses		
	Total Expenses (IV)		
	Profit / (Loss) before exceptional item and tax (III-IV)		
V	Exceptional item		
VI	Profit/loss before Tax (V-VI)		
VII	Tax expenses		
VIII	(1) Current Tax		
	(2) Deferred Tax		
IX	Profit/ (Loss) for the period from continuing operations (VI)		
X	Profit/ (Loss) from discontinued operations		
XI	Tax expense of discontinued operations		
XII	Profit/ (Loss) from discontinued operations (after tax) (X-XI)		



*Handwritten signature*



XIII	Profit/Loss for the period (IX+XII)		438,105	-182,266	261,309	340,905	-685,732
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss		-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss		-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)		438,105	-182,266	261,309	340,905	-685,732
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each		3,054,500	3,054,500	3,054,500	3,054,500	
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic		0.14	-0.06	0.09	0.11	-0.22
	2) Diluted		0.14	-0.06	0.09	0.11	-0.22
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic		0.00	0.00	0.00	0.00	0.00
	2) Diluted		0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic		0.14	-0.06	0.09	0.11	-0.22
	2) Diluted		0.14	-0.06	0.09	0.11	-0.22




# Statement of Asset and Liabilities

Particulars	As at	
	31/03/2018	31/03/2017
	Audited	Audited
	Standalone	Standalone
<b>ASSETS</b>		
<b>Non Current Assets</b>		
Property, plant and equipment	41,205,043	36,331,961
Capital work in progress	3,767,076	-
Other Intangible assets	-	-
Intangible assets under development	-	-
<b>Financial assets</b>		
Investment	-	-
Loans	20,600,000	21,500,000
Security Deposits	287,788	260,000
Other financial assets	-	-
Deferred tax assets (Net)	-	117,620
Other non current assets	-	-
<b>Total Non-Current Assets</b>	<b>65,859,908</b>	<b>58,209,581</b>
<b>Current Assets</b>		
Inventories	331,798	706,763
<b>Financial Assets:</b>		
Investments	-	-
Trade Receivables	223,362	-
Cash and Cash equivalents	33,300	243,400
Other Balances with banks	89,247	228,388
Loans	-	-
Other financial assets	-	-
Other Current assets	204,961	886,730
<b>Total Current Assets</b>	<b>882,668</b>	<b>2,065,281</b>
<b>Total Assets</b>	<b>66,742,576</b>	<b>60,274,862</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	30,545,000	30,545,000
Other Equity	14,740,266	14,399,361
<b>Total Equity</b>	<b>45,285,266</b>	<b>44,944,361</b>
<b>Non Current Liabilities</b>		
Financial liabilities		
Borrowings	7,500,000	7,500,000
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	127,351	-
Provisions	-	-
Other Non Current liabilities	-	-
<b>Total Non Current Liabilities</b>	<b>7,627,351</b>	<b>7,500,000</b>
<b>Current Liabilities</b>		
Financial liabilities		
Borrowings	-	-
Trade Payables	75,000	100,000
Other Financials liabilities	-	-
Provisions	261,680	154,000
Other Current liabilities	13,493,279	7,576,501
<b>Total Current Liabilities</b>	<b>13,829,959</b>	<b>7,830,501</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>66,742,576</b>	<b>60,274,862</b>

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on May 30, 2018 and the Statutory Auditors of the company have audited these financials results.

- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment.




- 5 There is change in accounting estimate, life of the Green House(Temporary Structure) from 3 to 4 Years and the effect of it has been reflected in the carrying value of asset as at 31.03.2018

Particulars	Depreciation as per New Life	Depreciation as per Old Life	Difference
Green house	348855.2	465140.27	116285.07

Due to improved technology in management it has become a very high class structure, which is not a temporary structure, during the period under consideration...

Place : Delhi  
Dated : 30/05/2018



For and on behalf of the Board of Directors of  
Genomic Valley Biotech Limited

  
Yogesh Agrawal  
Managing Director  
DIN: 01165288  
Address: G-74, Pushkar Enclave,  
Paschim Vihar, New Delhi-110063





# Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,  
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507  
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542

Email: [genomicvalley@gmail.com](mailto:genomicvalley@gmail.com); Visit: <http://www.genomicvalley.com>

## **Declaration of Un-Modified Audit Report pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We, Yogesh Agrawal, Managing Director and Lalit Shah, Chief Financial Officer of Genomic Valley Biotech Limited having its Registered Office at 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman, P.O. Tandaheri, Tehsil-Bahadurgarh, Distt- Jhajjar, Haryana-124507, hereby declare that A. K Khattar & Associates, Chartered Accountants (M. No. 084960), Statutory Auditors of the Company, has issued an Auditor Report with Un-Modified opinion on Audited Financial Results of the Company (Standalone) for the quarter and year ended 31<sup>st</sup> March, 2018.

This declaration is given pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

**For Genomic Valley Biotech Limited**

**Yogesh Agrawal**  
Managing Director  
DIN No. 01165288  
Address: G-74, Pushkar Enclave,  
Paschim Vihar, Delhi-110063



**Lalit Shah**  
Chief Financial Officer  
PAN No. BCHPS9526B  
Address: Flat No. 303, Pacific Tower,  
Omaxe City, Rohtak Road,  
Bahadurgarh-124507

**Dated: 30.05.2018**  
**Place: Delhi**